

Simultaneous Determination of Contents of Flavonol Glycosides and Terpene Lactones in Ginkgo Biloba Tablets by Ultra High Performance Liquid Chromatography Tandem Single Quadrupole Mass Spectrometry Detector

Lin Ma^{1,†}, Jie Zhang², Wei-rong Jin³ and Siwang Wang^{1,†,*}

¹Department of Chinese Materia Medica and Natural Medicines, Air Force Medical University, Xi'an 710032, Shanxi, China; malin98765@sohu.com

²Liaocheng Food and Drug Inspection and Testing Center, Liaocheng 252000, Shandong, China; 303102842@qq.com

³Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng 252000, Shandong, China; zjkjwr6353@163.com

*Correspondence: wangsiw@fmmu.edu.cn; Tel.: +86-29-847-725-19

Abstract: Ginkgo biloba leaf tablets is an effective ingredient in the treatment of cardiovascular and cerebrovascular diseases. In the process of drug production, the quality of ginkgo preparations is often controlled by measuring the content of seven ingredients in ginkgo leaves. To establish UPLC-MS multicomponent analysis method for ginkgo biloba tablets and to simultaneously determine the contents of quercetin (QUE), isorhamnetin (ISO), kaempferol (KAE) and Ginkgolide A

(GA), ginkgolide B (GB), ginkgolide C (GC) and bilobalide (BB) in ginkgo tablets. Waters Xbridge C18 (4.6×150mm, 3.5μm) column was used, mobile phase A was acetonitrile and mobile phase B was water (containing 0.10% formic acid). The injection volume was 10μL. Negative ion mode monitoring was conducted with ESI. Scanning range: m/z 100~1400. The detection ions of the seven tested components included m/z 301.0 (QUE), m/z 284.9 (KAE), m/z 315.1 (ISO), m/z 453.1 (GA), m/z 423.1 (G

B), m/z 439.0 (GC) and m/z 325.0 (BB), respectively. Within a space of 10min, flavonoids and terpene lactones in ginkgo biloba tablets were completely separated. The peak area exhibited an excellent linear relationship with the concentration. The sample recovery rate ranged from 91.74% to 109.77%. Precision RSDs of within-day and between-day were lower than 2.879% and 3.928% respectively. The method for determination of seven components in ginkgo biloba tablets displays good repeatability, recovery rate and precision, for which it can be applied to quality control of ginkgo biloba tablets.

Keywords: ginkgo biloba tablets; UPLC-MS; quantitative model; quercetin; isorhamnetin; kaempferol; ginkgolide A\B\C; bilobalide; simultaneous multielement measurements

1. Introduction

The major component of ginkgo biloba tablets is ginkgo extract, the main chemical components of which include ginkgo flavone and ginkgolide. In traditional Chinese medicine, it is known that Ginkgo biloba leaves and ginkgo nuts taste sweet, bitter and astringent. It is mild, with its leaves capable of the effects to promote blood circulation, nourish heart, as well as astringe lungs and intestine. The kernel of its seeds has the effects of moistening lung, alleviating asthma, reducing cough, inducing diuresis, preventing white ooze, inhibiting worms, relieving hangover, etc. Ginkgo biloba exocarp is sweet in taste, mild in nature and has the effects of enhancing vigour and tonifying deficiency [1-8]. Ginkgo biloba flavonoids are primarily present in ginkgo biloba leaves and seed kernels, with an especially high content found in ginkgo biloba leaves. Among them, quercetin, isorhamnetin and ft-nai have higher contents and are the main components of ginkgo biloba flavonoids. In the process of drug production, the quality of ginkgo biloba preparations is often controlled by detecting the contents of these three flavonoid aglycones [2-5]. Ginkgolide is an extraordinary component of ginkgo biloba and is contained in the seeds, leaves, roots and stems of ginkgo biloba. Ginkgolide A, B, C and bilobalide are also considered to be significant indicators of quality control for ginkgo biloba preparations [2-7].

At present, there are a variety of different methods for detecting ginkgo flavone and ginkgolide during ginkgo preparations [9-13]. However, there are few reports focused on multi-component mixed analysis of ginkgo preparations and there remain no reports on simultaneous determination and research into the seven components of ginkgo flavone and ginkgolide in ginkgo biloba tablets. In terms of detection instruments, ginkgolides are not absorbed in the ultraviolet region, for which it cannot be determined using HPLC-UV method. Nowadays HPLC-ELSD method is widely used [14,15]. However, the evaporative light detector has drawbacks of higher noise, lower sensitivity and poor stability. It requires complex sample processing to be used for detection [16]. In this experiment, simultaneous qualitative and quantitative analysis was conducted of ginkgo flavone and ginkgolide compounds without ultraviolet absorption by Ultra High Performance Liquid Chromatography Tandem Single Quadrupole Mass Spectrometry Detector (UPLC-MS).

2. Results

2.1 Quality Evaluation of Total Flavonoid Glycosides and Terpene Lactones Contents in Ginkgo Biloba Tablets

2.1.1 Determination of Total Flavonoid Glycosides Contents in Ginkgo Biloba Tablets

As specified in the first part of the 2015 edition of the Chinese Pharmacopoeia [17], the total flavonol glycosides in specification A shall be $19.2\text{mg}\cdot\text{tablet}^{-1}$ as a minimum and the total flavonol glycosides content in specification B shall be $9.6\text{mg}\cdot\text{tablet}^{-1}$ as a minimum ($n=3$). The results demonstrated that the content of total flavonol glycosides in ten batches of ginkgo biloba tablets produced by five manufacturers was compliant, as shown in Table 1.

Table 1. Determination of total flavonoid glycosides contents in ginkgo biloba tablets ($n=3$).

Numbering	sample	Specification (mg)	Mass fraction ($\text{mg}\cdot\text{tablet}^{-1}$)
1	A1	19.2	23.1
2	A2	19.2	22.2
3	A3	19.2	22.4
4	A4	19.2	22.3
5	A5	19.2	22.0

6	A6	19.2	22.9
7	B1	9.6	13.5
8	B2	9.6	12.6
9	B3	9.6	11.3
10	B4	9.6	12.1

2.1.2 Determination of Terpene Lactones Contents in Ginkgo Biloba Tablets

As specified in the first part of the 2015 edition of the Chinese Pharmacopoeia [17], the terpene lactones in specification A shall be 4.8mg·tablet⁻¹ as a minimum and the terpene lactones content in specification B shall be 2.4mg·tablet⁻¹ as a minimum(n=3). The results indicated that the content of terpene lactones in ten batches of ginkgo biloba tablets produced by five manufacturers was compliant, as shown in Table 2.

Table 2. Determination of terpene lactones contents in ginkgo biloba tablets (n=3).

Numbering	sample	Specifications (mg)	Mass fraction (mg·tablet ⁻¹)
1	A1	4.8	5.4
2	A2	4.8	5.1
3	A3	4.8	6.0
4	A4	4.8	5.0
5	A5	4.8	5.9
6	A6	4.8	9.0
7	B1	2.4	3.1
8	B2	2.4	3.1
9	B3	2.4	3.4
10	B4	2.4	3.1

2.2 Simultaneous Determination of 7 Components in Ginkgo Biloba Tablets by UPLC-MS and Validation of Methodology

2.2.1 Standard Curve, Detection Limit and Quantitative Limit

A precise measurement was taken of the series of standard solutions and the determination was performed according to the "chromatographic conditions"(n=3). The concentrations of QUE, KAE, ISO, GA, GB, GC, BB were taken as abscissa, the peak areas were taken as ordinate and a linear regression equation was derived. The results indicated that the linear relationship of each standard was excellent within a certain range. The mixed reference substance solution was diluted incrementally. The concentration of each reference substance when S/N=10:1 and S/N=3:1 was regarded as the quantitative limit and detection limit [18]. The quantitative limit range was 5.0*10⁻⁶ to 1.0*10⁻⁵ mg·mL⁻¹ and the detection limit range was 1.0*10⁻⁵ to 2.5*10⁻⁵ mg·mL⁻¹, as shown in Table 3.

90

Table 3. Standard curve of 7 components in ginkgo biloba tablets (n=3).

Components	Linear equation	r ²	Concentration range (mg·mL ⁻¹)	LOQ (mg·mL ⁻¹)	LOD (mg·mL ⁻¹)
QUE	y=21731+11.91x	0.9997	0.005~0.100	1.0×10 ⁻⁵	2.5×10 ⁻⁵
KAE	y=119304+14.53x	0.9991	0.005~0.100	1.0×10 ⁻⁵	2.5×10 ⁻⁵
ISO	y=102424+16.15x	0.9992	0.005~0.100	1.0×10 ⁻⁵	2.5×10 ⁻⁵
GA	y=44533+11.65x	0.9992	0.005~0.100	5.0×10 ⁻⁶	1.0×10 ⁻⁵
GB	y=66218+12.03x	0.9997	0.005~0.100	5.0×10 ⁻⁶	1.0×10 ⁻⁵
GC	y=42527+8.44x	0.9996	0.005~0.100	5.0×10 ⁻⁶	1.0×10 ⁻⁵
BB	y=61237+12.66x	0.9997	0.005~0.100	5.0×10 ⁻⁶	1.0×10 ⁻⁵

91 2.2.2 Sample Recovery Rate

92 After one tablet of sample A1 was taken and re-extracted.1000μL of filtered extract was taken.
 93 According to the ratio of 1:0.5(low),1:1.0 (medium) and 1:1.5(high) of the content of each measured
 94 chemical substance, standard solution with various substance concentrations of 1mg·mL⁻¹ was added
 95 respectively. In addition, the recovery rates of high, medium and low concentration substances were
 96 tested after the standard was added. Based on the determination of "chromatographic
 97 conditions"(n=3), the recovery rate of this method was 91.74%~109.77%. The results confirmed that
 98 the recovery rate of this method could satisfy the requirements, as shown in Table 4.

99 **Table 4.** The recovery rate of seven components in ginkgo biloba tablets (n=3).

Component	Sample content	Addition of standard substance	Measured quantity	Recovery rate	Average recovery rate	RSD
	(mg)	(mg)	(mg)	(%)	(%)	(%)
QUE	0.112	0.0560	0.1735	109.82	101.29	2.19
		0.1120	0.2185	95.08		0.41
		0.1680	0.2783	98.97		3.00
KAE	0.213	0.1065	0.3258	105.95	97.65	1.16
		0.2130	0.4131	93.92		0.87
		0.3195	0.5104	93.09		1.54
ISO	0.175	0.0875	0.2707	109.42	102.04	3.14
		0.1750	0.3587	104.97		3.15
		0.2625	0.4158	91.74		0.00
GA	0.069	0.0345	0.1056	106.03	101.93	1.65

		0.0690	0.1389	101.25		0.20
		0.1035	0.1710	98.51		3.23
GB	0.046	0.0230	0.0694	101.82	101.18	2.52
		0.0460	0.0920	99.94		2.97
		0.0690	0.1162	101.78		2.79
GC	0.066	0.0330	0.1007	105.28	104.28	2.37
		0.0660	0.1357	105.62		0.41
		0.0990	0.1669	101.96		2.39
BB	0.125	0.0625	0.1935	109.58	99.19	1.71
		0.1250	0.2415	93.17		0.97
		0.1875	0.3028	94.84		0.79

2.2.3 Precision

A precise measurement was taken of the same mixed reference substance solution. The mixed standard solution of low, medium and high concentration was prepared and determined based on "chromatographic conditions" (n=6). Intra-day precision refers to six parallel tests within one day. Daytime precision refers to two parallel tests within one day for three consecutive days. The results confirmed that the intra-day and inter-day precision of the method could satisfy the requirements, as shown in Table 5.

Table 5. Intraday and daytime precision of seven components in ginkgo biloba tablets (n=6, $\bar{x} \pm SD$).

Comp onent	Concentration (mg·mL ⁻¹)	Intraday		Daytime		
		Mean±SD	RSD (%)	Concentration (mg·mL ⁻¹)	Mean±SD	RSD (%)
QUE	0.0391	0.0391±0.0006	1.437	0.0395	0.0395±0.0004	0.912
	0.0804	0.0804±0.0006	0.692	0.0809	0.0809±0.0007	0.907
	0.1233	0.1233±0.0034	2.732	0.1235	0.1235±0.0026	2.110
KAE	0.0672	0.0672±0.0019	2.879	0.0668	0.0668±0.0024	3.651
	0.1347	0.1347±0.0030	2.225	0.1352	0.1352±0.0032	2.360
	0.1835	0.1835±0.0030	1.626	0.1859	0.1859±0.0047	2.532
ISO	0.0365	0.0365±0.0003	0.899	0.0367	0.0367±0.0004	0.975
	0.0785	0.0785±0.0011	1.383	0.0787	0.0787±0.0011	1.444
	0.1704	0.1704±0.0017	0.987	0.1697	0.1697±0.0013	0.749

GA	0.0232	0.0232±0.0006	2.566	0.0234	0.0234±0.0006	2.601
	0.0500	0.0500±0.0010	2.030	0.0502	0.0502±0.0013	2.580
	0.0674	0.0674±0.0009	1.347	0.0694	0.0694±0.0021	3.021
GB	0.0141	0.0141±0.0003	2.126	0.0141	0.0141±0.0003	2.480
	0.0328	0.0328±0.0003	0.975	0.0327	0.0327±0.0004	1.078
	0.0476	0.0476±0.0004	0.921	0.0484	0.0484±0.0019	3.928
GC	0.0214	0.0214±0.0006	2.668	0.0213	0.0213±0.0004	1.893
	0.0487	0.0487±0.0006	1.304	0.0488	0.0488±0.0007	1.335
	0.0706	0.0706±0.0008	1.186	0.0719	0.0719±0.0027	3.814
BB	0.0424	0.0424±0.0004	0.834	0.0426	0.0426±0.0005	1.240
	0.0898	0.0898±0.0023	2.517	0.0906	0.0906±0.0034	3.701
	0.1144	0.1144±0.0031	2.721	0.1135	0.1135±0.0035	3.083

2.2.4 Repeatable

Sample 1 was taken. Five sample solutions were prepared in parallel according to the preparation items of the sample solution and determined based on the "chromatographic conditions"(n=3). The results indicated that the method was capable of excellent repeatability, as shown in Table 6.

Table 6. Repeatability of seven components in ginkgo biloba tablets (n=3).

Sample	Measured content (mg·mL ⁻¹)					Average	RDS
Component	1	2	3	4	5	(mg·mL ⁻¹)	(%)
QUE	0.1232	0.1226	0.1231	0.1231	0.1236	0.1231±0.00030	0.27
KAE	0.1945	0.1956	0.1943	0.1935	0.1959	0.1948±0.00154	0.79
ISO	0.1694	0.1721	0.1707	0.1726	0.1706	0.1711±0.00128	0.74
GA	0.0647	0.0668	0.0663	0.0669	0.0662	0.0661±0.00046	0.69
GB	0.0481	0.0486	0.0487	0.0487	0.0487	0.0486±0.00018	0.35
GC	0.0705	0.0720	0.0721	0.0727	0.0721	0.0719±0.00034	0.45
BB	0.1115	0.1115	0.1111	0.1112	0.1110	0.1113±0.00068	0.61

2.2.5 Stability

Sample 1 was taken. According to the preparation items of the sample solution, seven samples of the sample solution were prepared in parallel. Based on the "chromatographic conditions"(n=3), the samples were injected for detection at 0, 4, 8, 12, 18, 24 and 48 hours respectively. The results

revealed that the sample solution was capable of remarkable stability within forty-eight hours, as shown in Table 7.

Table 7. Stability of seven components in ginkgo biloba tablets (n=3).

Sample	Measured content (mg·mL ⁻¹)							Average	RDS
Component	0	4	8	12	18	24	48	(mg·mL ⁻¹)	(%)
QUE	0.0798	0.0804	0.0799	0.0806	0.0803	0.0808	0.0801	0.0803±0.00053	0.66
KAE	0.1513	0.1530	0.1514	0.1532	0.1533	0.1533	0.1514	0.1524±0.00157	1.03
ISO	0.0806	0.0802	0.0805	0.0814	0.0796	0.0824	0.0824	0.0810±0.00092	1.12
GA	0.0481	0.0485	0.0487	0.0494	0.0499	0.0518	0.0514	0.0497±0.00096	1.93
GB	0.0292	0.0294	0.0295	0.0293	0.0293	0.0295	0.0295	0.0294±0.00013	0.38
GC	0.0516	0.0518	0.0520	0.0517	0.0521	0.0521	0.0519	0.0519±0.00020	0.40
BB	0.0892	0.0902	0.0905	0.0909	0.0909	0.0905	0.0915	0.0905±0.00093	1.03

2.2.6 Simultaneous Determination of Seven Components Content in Ginkgo Biloba Tablets


Totally ten batches of ginkgo leaf samples were taken and determined based on the terms of "preparation of test solution" and "chromatographic conditions"(n=3). The established analysis method was effective in separating the components in ginkgo biloba tablets and a quantitative analysis was performed of seven components. After calculation, the results revealed that QUE, KAE, ISO and BB are higher than other components in ten batches of ginkgo biloba tablets, as shown in Table 8. The LC-MS spectra of the 7 components reference substance were observed to be consistent with the corresponding component spectra of the sample, as shown in Figures 1 and 2. And the primary mass spectra of the reference substance and the sample are presented in Figures 3, 4, 5, 6, 7, 8 and 9.

Table 8. Contents of seven components in ginkgo biloba tablets in different batches (n=3, $\bar{x} \pm SD$, mg·g⁻¹).

Sample							
/Component	QUE	KAE	ISO	GA	GB	GC	BB
A1	5.363±0.007	10.202±0.051	8.357±0.014	3.309±0.005	2.214±0.007	3.139±0.004	5.989±0.001
A2	5.684±0.002	10.128±0.012	8.291±0.007	3.387±0.003	2.392±0.004	3.199±0.004	6.356±0.002
A3	4.907±0.005	7.749±0.012	6.753±0.006	2.632±0.020	1.904±0.004	2.803±0.007	4.496±0.007
A4	5.826±0.003	7.940±0.027	7.933±0.002	2.941±0.002	2.015±0.007	2.798±0.002	4.847±0.008
A5	10.658±0.007	13.680±0.009	14.492±0.006	4.240±0.002	3.138±0.030	4.274±0.011	6.454±0.002
A6	5.493±0.006	7.980±0.006	7.245±0.002	3.222±0.002	1.896±0.001	2.405±0.013	4.334±0.004
B1	4.306±0.003	4.793±0.002	4.381±0.003	1.767±0.014	1.247±0.004	1.646±0.005	3.332±0.001


B2	4.342±0.005	5.168±0.005	4.948±0.004	2.001±0.002	1.368±0.001	1.846±0.006	3.504±0.005
B3	5.634±0.004	7.157±0.024	6.649±0.025	2.754±0.004	1.736±0.002	1.953±0.002	4.053±0.002
B4	5.318±0.004	7.100±0.007	6.744±0.026	2.606±0.006	1.646±0.010	1.841±0.047	3.731±0.004

132



133


Figure 1. LC-MS chromatogram of seven components reference substance from ginkgo biloba.



Time min


134

Figure 2. LC-MS chromatogram of seven component samples from ginkgo biloba tablets.




135

Figure 3. Primary mass spectrum of QUE reference substance (left) and sample (right).




136

Figure 4. Primary mass spectrum of KAE reference substance (left) and sample (right).




137


Figure 5. Primary mass spectrum of ISO reference substance (left) and sample (right).



138 **Figure 6.** Primary mass spectrum of GA reference substance (left) and sample (right).



139 **Figure 7.** Primary mass spectrum of GB reference substance (left) and sample (right).



140 **Figure 8.** Primary mass spectra of GC reference substance (left) and sample (right).




Figure 9. Primary mass spectrum of BB reference substance (left) and sample (right).

3. Discussion

High performance liquid chromatography-mass spectrometry (HPLC-MS) has been extensively applied to the quality research of drugs due to its impressive specificity and higher sensitivity [19-24]. In this experiment, the greatest advantage displayed by the UPLC-MS was simple operation. It took as little as five minutes of mass spectrometry equilibrium time to complete qualitative analysis of samples. Moreover, it can be used for qualitative and quantitative analysis of compounds that is incapable of ultraviolet absorption. Negative ion mode monitoring was conducted by Electron Spray Ionization and the results demonstrated that the relative molecular mass parameters were respectively QUE301.0, KAE284.9, ISO315.1, GA453.1, GB423.1, GC439.0 and BB325.0, which was discovered to be consistent with literature reports [22]. Not only does this method provide reference and basis for the quality control of ginkgo biloba tablets, it also lays a solid foundation for further study on the pharmacodynamical characteristics of in vivo index components of ginkgo biloba after oral administration in rats. However, this method remains subjected to various limitations and some drawbacks are exposed. In this sense, further research is deemed necessary to improve the quality control of ginkgo biloba tablets and to figure out their efficacy.

4. Materials and Methods

4.1 Instruments and Drug Testing

Measuring apparatus: Electronic Balance, METTLER TOLEDO, USA; Ultrasonic Instrument, Shanghai Yixin, China; Centrifuge, Zhongke, China; Ultra high performance liquid chromatography system (UHPLC), Agilent 1260; Mass spectrometer (MS), Agilent 6120; N-EVAP -24 Organomation of the United States.

Standard substance: quercetin (QCT) batch number 181123, content $\geq 98.05\%$, kaempferol (KAE) batch number 10128, content $\geq 98.54\%$, isorhamnetin (ISR) batch number 181217, content $\geq 98.07\%$, ginkgolide A (GA) batch number 180412, content $\geq 99.32\%$, ginkgolide B (GB) batch number 180210, content $\geq 98.97\%$, ginkgolide C (GC) batch number 180330, content $\geq 98.8\%$, bilobalide (BB) batch number 180615, content $\geq 99.69\%$. They are all purchased from Beijing Century Aoke Biotechnology Co.LTD.

Reference substance: ginkgo biloba tablets five manufacturers, ten batch numbers, specifications: 19.2/4.8mg-tablet-1 and 9.6/2.4mg-tablet⁻¹. They are designated A1, A2, A3, A4, A5, A6, B1, B2, B3 and B4 respectively.

Reagent: methanol, chromatographically pure, Thermo Fisher of USA; Acetonitrile, Chromatographically pure, Thermofisher of USA; Dichloromethane, Analytical pure, national medicine reagent chemical reagent co. LTD; Deionized water, self-made in laboratory, other reagents are all analytically pure.

4.2 content determination

4.2.1 Quality Evaluation of Total Flavonoid Glycosides and Terpene Lactones in Ginkgo Biloba Tablets: According to the content determination method of total flavonoid glycosides and terpenoid lactones in ginkgo biloba tablets of the first part of Chinese pharmacopoeia 2015 edition [17], ten batches of ginkgo biloba tablets collected from different manufacturers were detected.

4.2.2 Simultaneous Measurements of Content of Seven Components in Ginkgo Biloba Tablets by UPLC-MS Method

Preparation of Test Sample Solution: Quantitative (one tablet for samples numbered A1-A6 and two tablets for samples numbered B1-B4) was accurately weighed after being crushed and added into 5.0mL methylene chloride to dissolve. The sample bottle was sealed and soaked for eight hours and ultrasonically dispersed after the solvent fully infiltrated the tablet carrier. During the ultrasonic process, the solution was kept at a temperature below thirty degrees Celsius by pausing and adding ice cubes. After the effective components in the sample were completely dissolved, the supernatant was centrifuged and filtered. Afterwards, 1ml was measured and diluted with acetonitrile for later use.

Preparation of Standard Solution: The reference substances including ginkgolide A, ginkgolide B, ginkgolide C and bilobalide, quercetin, isorhamnetin and appropriate amount of kaempferol were precisely weighed, respectively. Then, dichloromethane was added to prepare the reference substance solution of about 1mg·mL⁻¹. With appropriate amount of each reference substance solution taken respectively, methylene chloride was added to prepare mixed reference substance solution with appropriate concentration. They were stirred up sufficiently and filtered using 0.45μm filter membrane for later use.

Preparation of Series of Concentration Standard Solution: 0.5, 1.0, 2.0, 4.0 and 8.0mL of the above mixed reference solution were measured accurately and placed in 10mL volumetric flasks respectively. Acetonitrile was added, diluted to scale and stirred up sufficiently for later use.

Chromatographic Conditions: Waters Xbridge C18 (4.6×150mm, 3.5μm) column was used, mobile phase A was acetonitrile and mobile phase B was water (containing 0.10% formic acid). It is gradient eluted (0 to 2 min, 0%A→5%A; 2 to 4min, 5%A→95%A, 4 to 30min, 95%A). Prior to each injection, the mobile phase A-B (50:50) pre-equilibrium was applied for a period of 5min, the flow rate was 1.5mL·min⁻¹, the column temperature was 30°C and the injection volume was 10μL.

Mass Spectrometry Conditions: Negative ion mode monitoring was carried out with Electron Spray Ionization. Quantitative mode was adopted. Scanning range m/z was 100~1400, Capillary voltage

was 3.8kv. Spray pressure was 60psi and ion source temperature was 650°C. The interface was heated and nitrogen was introduced throughout the process.

Determination Method: 10μL of test sample solution was accurately measured. According to "chromatographic conditions" and "mass spectrometry conditions", LC-MS was applied for determination.

5. Conclusions

In this study, a total of 7 components in ginkgo biloba tablets were determined simultaneously by UPLC-MS. Methodological investigation revealed that this method was capable of determining the content of ginkgo flavonoids and ginkgolides in ginkgo biloba tablets and that of ginkgo flavonoids and ginkgolides in ginkgo biloba leaves. This article analyzed the limitations and shortcomings of the experiment. First of all, ginkgo biloba is an extract in traditional Chinese medicine, which is made use of widely in China, Japan, South Korea, Korea and Southeast Asia. However, it remains rarely used in other countries and regions. Therefore, the retrieval of relevant literature is subjected to certain limitations. Secondly, due to the influence exerted by the areas of production, the processing of the original medicinal materials of ginkgo biloba tablets of each batch, the processing techniques and the content of 7 effective components in ginkgo biloba tablets are different to some extent. However, the results of the sample for the test showed that the quantity of 7 active ingredients in Ginkgo biloba tablets was appropriate to the standard. This method provided a reference and basis for the quality control of ginkgo biloba tablets, in addition to laying a foundation for the further pharmacokinetic study of ginkgo biloba tablets in the future.

Author Contributions: For research articles with four authors. The study was designed by LM and SSW. The experiments, as well as data analysis were conducted by LM, JZ and WRJ. JZ contributed analysis tools; The results were interpreted by LM and SSW. All the authors have made critical revision to the important knowledge content.

Funding: This work was funded by a grant from the Science and Technology Innovation Project of Shaanxi province, China (No. 2015SF2-08-01), the Key research laboratory of traditional Chinese medicine and natural medicine in Shaanxi province (No. 2015-164) as well as the subsidy from the Project of Shaanxi engineering technology research center (No. S2018-ZC-GCZXXY-SF-0005).

Acknowledgments: We appreciate all the reviewers for their suggestions.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

KA: aempferol

ISO: isorhamnetin

GA: ginkgolide A

GB: ginkgolide B

GC: ginkgolide C

BB: bilobalide

ESI: Electron Spray Ionization

UPLC-MS: ultra-high performance liquid chromatography-mass spectrometer

HPLC-UV: high performance liquid chromatography- ultraviolet

HPLC-ELSD: high performance liquid chromatography- evaporative light-scattering detector

LC-M: High performance liquid chromatography-mass spectrometer

RSD: Relative Standard Deviation

246 **References**

- 247 He, W.Y. Summary of studies on the selection and breeding of improved ginkgo varieties and high-yield
248 cultivation techniques in China. *Gansu Nongye* **2013**, 378, 92-94.
- 249 Sun, F.; Wang, L.; Yan, B.; Peng, X. Chemical components and pharmacological effects of ginkgo biloba extracts.
250 *Shandong Journal of Traditional Chinese Medicine* **2014**, 33, 221-223.
- 251 Zhang, H.M. The chemical constituents and pharmacological activities of natural medicine, ginkgo biloba.
252 *Journal of Capital Normal University(Natural Sciences Edition)* **2014**, 35, 41-46.
- 253 Liu, X.P.; Zang, H.C.; Yu, H.L. Research progress and application prospect of ginkgo biloba extract. *Journal of*
254 *Pharmaceutical Research* **2014**, 33, 721-723.
- 255 Wang, G.Y.; Zhu, J.J.; Lou, F.C. Chemical constituents from the exopleura of Ginkgo biloba and inhibition test of
256 total ginkgolide acids against phytopathogenic fungi. *Journal of China Pharmaceutical University* **2014**, 45, 170-174.
- 257 Tian, Q.Y.; Gong, L.L. Research progress in ginkgo terpene lactones. *Central South Pharmacy* **2016**, 14, 838-841.
- 258 Zhang, P.F.; Liao, L.J.; Deng, Z.; Tan, Y.P. Research progress of pharmacological effects and clinical application
259 of ginkgo biloba extract. *Liaoning Journal of Traditional Chinese Medicine* **2017**, 44, 426-429.
- 260 Bao, Y.R.; Zhang, H.R.; Liu, L.T. Optimization of extraction process of flavonoids from ginkgo biloba leaves and
261 antioxidant activity. *Journal of Henan University of Technology(Natural Science Edition)* **2016**, 37, 96-99.
- 262 Xu, X.G.; Yang, D.B.; Yu, R.C. Study on determination method of flavonoids in ginkgo leaves *Shandong*
263 *Pharmaceutical Industry* **1999**, 19, 20-21.
- 264 She, J.H.; Liu, Z.L. Analysis of flavonoid extracts from ginkgo leaves (ginkgo biloba) by SFE-HPLC. *Chinses*
265 *Traditional and Herbal Drugs* **2000**, 31, 101-103.
- 266 Bi, Y.M.; Sun, G.X.; Yu, X.M. Determination of ginkgolides in ginkgo leaf extract and dipyrindamole injection by
267 HPLC-ELSD. *Central South Pharmacy* **2007**, 5, 124-127.
- 268 Yang, Y.F.; Xia, Y.Y. Progress on determination methods of terpene lactones in ginkgo leaves and their
269 preparations. *Xian Dai Yao Wu Yu Lin Chuang* **2000**, 15, 61-66.
- 270 Lv, F.S.; Chen, W.; Feng, F.; Zhang, Z.X. The contents of terpenelactones in the ginkgo injection. *Journal of China*
271 *Pharmaceutical University* **2001**, 32, 34-36.

- 272 Liu, H.; Huang, S.W.; Guo, Y.; Xiong, Y. Determination of flavonol glycosides and terpene lactones in Ginkgo
273 biloba extract from different pharmaceutical factories by HPLC. *China Journal of Traditional Chinese Medicine and*
274 *Pharmacy* **2015**, 30, 598-601.
- 275 Gong, L.L.; Tian, J.Z. Determination of terpene lactones in ginkgo biloba extract by HPLC-ELSD. *Journal of*
276 *Shandong University of Traditional Chinese Medicine* **2013**, 37, 69-70.
- 277 Ou, Q.; Zhang, L.Y.; Qian, Y.X.; Kang, J.C.; He, J. Determination of flavonoids and lactone in shuxuening injection
278 by HPLC. *Journal of Guizhou University (Natural Science)* **2010**, 27, 34-37.
- 279 StatePharmacopoeiaCommittee. Pharmacopoeia of the People's Republic of China (Part I) *Beijing: China*
280 *Pharmaceutical Science and Technology Association* **2015**, 1491-1492.
- 281 Qiao, S.; Shi, R.; Jiang, W.J.; Shu Jie, L.U.; Wang, Q.; Zhang, L.T. Simultaneous determination of six components
282 in zixinyin oral liquid by LC-MS/MS. *Chinese Traditional Patent Medicine* **2011**, 33, 456-460.
- 283 Liang, W.L.; Xie, D.W.; Ding, G.; Xu, D.H.; Sun, Y.C.; Lian, Y.P.; LI, Y.J.; Xiao, W. Quantitative and qualitative
284 evaluation on tablets of ginkgo biloba leaves using fingerprint and LC-MS analysis. *China Journal of Chinese Materia*
285 *Medica* **2015**, 40, 1738-1743.
- 286 Li, L.F.; Sun, G.X. Quantified fingerprints of ginkgo tablet by HPLC and content determination of four
287 components. *Chinese Journal of Experiment Traditional Medical Formulae* **2014**, 20, 52-57.
- 288 Tong, R.F.; Lin, H.; Li, W.C.; Zhang, N. Determination of ginkgolid A, B, and C, and bilobalide from Yinxingye
289 Tablets by HPLC-MS method. *Drugs & Clinic* **2017**, 32, 386-389.
- 290 Ren, Y.P.; Chang, L.; Cao, L.; Zhi, X.R.; Zhang, L.T. Simultaneous determination of terpene lactones and favonoid
291 aglycones in Shuxuening injection by HPLC-MS. *Chinese Journal of Pharmaceutical Analysis* **2013**, 33, 220-224.
- 292 Xu, H.J.; Ji, X.; Chen, Z.; Lu, S.J.; Zhang, L.T. Simultaneous determination of seven coumarins in qingxuan tablets
293 by HPLC-MS. *Chinese Pharmaceutical Journal* **2011**, 46, 1526-1529.
- 294 Ganzera, M.; Sturm, S. Recent advances on HPLC/MS in medicinal plant analysis—an update covering 2011-
295 2016. *Journal of Pharmaceutical and Biomedical Analysis* **2017**, 147, 211-233.
- 296